GLP-1 Drug Options: Biomarker Context & Personalization

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The GLP-1 receptor agonist class encompasses semaglutide, tirzepatide, retatrutide, dulaglutide, and liraglutide—each with distinct mechanisms, potency profiles, and clinical efficacy data. Understanding these differences is foundational to informed treatment conversations with qualified healthcare providers.

Beyond branded options, patients increasingly explore compounded formulations for cost and access. However, selecting among GLP-1 variants requires more than efficacy data—it demands attention to individual biomarkers, genetic predispositions, and treatment goals to support genuinely personalized care.

The GLP-1 Class: Mechanism, Potency, and Clinical Profiles

GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a hormone that regulates blood glucose and satiety. Semaglutide and liraglutide are selective GLP-1R agonists; tirzepatide and retatrutide activate both GIPR, dual pathways offering greater weight and glucose effects in clinical trials.

Semaglutide is available as weekly injection (Ozempic, Wegovy) or oral tablet (Rybelsus). Tirzepatide is injected weekly (Mounjaro, Zepbound). Dulaglutide (Trulicity) is weekly injection. Retatrutide, triple agonist combining GIPR, and GCR pathways, remains under investigation. Compounded versions of semaglutide and tirzepatide are accessible through licensed 503A pharmacies.

Comparative GLP-1 Options: Efficacy, Frequency, and Route

Clinical trials show tirzepatide achieving greater A1C reduction and weight loss than semaglutide at equivalent doses. Retatrutide triple agonist data suggests even larger glycemic and weight benefits, though clinical availability remains limited. Choice among agents depends on efficacy targets, injection tolerance, and individual response patterns informed by biomarker context.

GLP-1 Agent	Dosing Frequency	Primary Route	Mechanism	Key Clinical Outcome Data
Semaglutide	Weekly	Injection or Oral	GLP-1R selective	A1C reduction ~1.5–1.8%, weight loss 5–15%
Tirzepatide	Weekly	Injection	GLP-1R + GIPR dual	A1C reduction ~2.0–2.5%, weight loss 15–22%
Retatrutide	Weekly	Injection	GLP-1R + GIPR + GCR triple	A1C reduction ~2.0–2.7%, weight loss 24%+ (phase 3)
Dulaglutide	Weekly	Injection	GLP-1R selective	A1C reduction ~1.5%, weight loss 2–4%
Liraglutide	Daily	Injection	GLP-1R selective	A1C reduction ~1.5%, weight loss 2–3%

Genetic Predispositions in Peptide Pathways: Beyond Clinical Trials

Individual genetic variation in GLP-1 receptor (GLP1R), GIP receptor (GIPR), melanocortin-4 receptor (MC4R), and FTO genes shapes how bodies respond to GLP-1 agonist therapy. Variants in rs6923761 (GLP1R), rs1800437 (GIPR), rs17782313 (MC4R), and rs9939609 (FTO) influence receptor sensitivity and metabolic regulation, creating physiologic diversity beyond trial averages.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to GLP-1 medications or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Provider Decision Framework: Who Benefits from Which GLP-1 Class Member

Selecting among GLP-1 options requires integration of clinical efficacy data, individual risk factors, tolerability history, access, and cost. Patients with type 2 diabetes and obesity may benefit from dual agonists (tirzepatide); those seeking oral convenience may consider compounded oral semaglutide; daily-injection preference patients may discuss liraglutide or dulaglutide.

Genetic predisposition data—especially variants indicating robust GIPR or GLP1R signaling—can anchor these conversations with evidence of individual variation. Compounded semaglutide and tirzepatide through licensed 503A pharmacies offer cost-effective alternatives to branded formulations, extending access for patients for whom standard options are prohibitively expensive or geographically inaccessible.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Testing examines four key genetic variants (GIPR rs1800437, MC4R rs17782313, FTO rs9939609) that influence peptide receptor function and metabolic capacity. This biomarker context may help provide crucial nuance in GLP-1 agent selection conversations—revealing whether your genetic profile suggests stronger receptor signaling potential or metabolic barriers that might inform choice between selective versus dual agonists.

The genetic test does not predict which branded or compounded GLP-1 drug will work best for you. Rather, it reveals predispositions in peptide pathways that should be interpreted with a qualified healthcare provider. Patients with favorable GIPR variants, for example, might be candidates for dual-agonist therapy like tirzepatide or retatrutide; those with FTO risk alleles may benefit from agents with robust weight-management outcomes.

Armed with genetic predisposition context and clinical efficacy data, you can have a more informed conversation with your provider about whether semaglutide, tirzepatide, or another GLP-1 option aligns with your physiology, treatment goals, and access constraints. PlexusDx compounded semaglutide injection ($189/mo) and compounded tirzepatide injection ($289/mo) from licensed 503A pharmacies extend affordable access once your provider recommends the best agent for you.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Which medications does this article count as part of the GLP-1 landscape?

It covers semaglutide, tirzepatide, retatrutide, dulaglutide, and liraglutide. The post sorts them by mechanism: semaglutide, dulaglutide, and liraglutide act selectively at the GLP-1 receptor, tirzepatide adds GIP receptor activity, and retatrutide is described as a triple agonist that also targets the glucagon receptor and remains under investigation.

How do dosing frequency and route compare across the agents listed?

The article's table lists semaglutide as weekly and available by injection or oral tablet, tirzepatide and dulaglutide as weekly injections, and liraglutide as a daily injection. It names Ozempic and Wegovy as semaglutide injectables, Rybelsus as the tablet, Mounjaro and Zepbound as tirzepatide, and Trulicity as dulaglutide.

Which agents does the comparison table rank lowest for weight reduction?

Dulaglutide and liraglutide, both listed as selective GLP-1 agonists with roughly 1.5 percent A1C reduction and weight loss in the low single digits. The article contrasts them with semaglutide and tirzepatide, which it credits with substantially larger weight effects, and frames selection as balancing efficacy against injection tolerance and individual response.

Can a patient actually obtain retatrutide based on what this article says?

The post says retatrutide remains under investigation, yet it also places efficacy figures for that agent in the same comparison table as marketed products, which blurs the distinction. An investigational agent is not available outside a clinical trial, so status is worth confirming with a provider rather than inferring from the table.

What factors besides efficacy does the post say should drive agent selection?

It says selection requires integrating clinical efficacy data with individual risk factors, tolerability history, access, and cost. The article offers examples: patients wanting oral convenience may consider compounded oral semaglutide, while those with a preference about injection frequency may raise liraglutide or dulaglutide with their provider instead.

Related Reading

• History Of Glp 1 Drugs Plexusdx
• Glp 1 Agonist Drugs
• Glp 1 Drugs List
• Drugs Glp 1

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.